论文部分内容阅读
以高脂血症鹌鹑模型研究了市售红曲H－04和利用现代生物技术自制的新红曲H－18的血脂调节作用。结果显示，红曲H－04和红曲H-18均具有明显降低高脂血症鹌鹑血清总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL－C）的作用；红曲H－18各剂量组对TG、LDL－C的降低作用大于红曲H－04相应剂量组，但统计学上无显著性差异；红曲H－18高剂量组和红曲H-04高剂量组对TC的降低作用有显著性差异（P＜0．05）。提示红曲H－18比红曲H－04具有更强的降血脂活性。
The hyperlipidemic quail model was used to study the regulation of blood lipid on the commercially available Monascus H-04 and the new Monascus melon H-18 made by modern biotechnology. The results showed that both Monascus H-04 and Monascus H-18 could significantly reduce the levels of serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) in hyperlipidemic quails. Red yeast H-18 dose group TG, LDL-C decreased more than the corresponding dose of red yeast H-04 dose group, but no statistically significant difference; High-dose group had a significant difference in the reduction of TC (P <0.05). Suggesting that H-18 has greater hypolipidemic activity than H-04.